NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report released on Thursday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 4.5 %

NASDAQ:NURO opened at $4.21 on Thursday. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The firm has a market cap of $8.59 million, a price-to-earnings ratio of -0.92 and a beta of 2.20. The company’s 50-day moving average is $4.03 and its two-hundred day moving average is $3.88.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The business had revenue of $0.59 million during the quarter. During the same period in the previous year, the business earned ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.